LIN Liang

Dr. LIN Liang is an Adjunct Assistant Professor at the National University of Singapore's Saw Swee Hock School of Public Health and serves as Head (Health Technology Assessment) at the Agency for Care Effectiveness under Singapore's Ministry of Health. Her work focuses on Health Technology Assessment (HTA), health economics, and value-based pricing negotiations to enhance healthcare accessibility and system efficiency. She holds a Master of Science in International Health Technology Assessment and a Bachelor of Science (Pharmacy) with First Class Honours.

Her research emphasizes cost-effectiveness analysis, clinical outcomes evaluation, and policy development for pharmaceuticals and medical technologies. Notable projects include optimizing biosimilar use strategies, evaluating hepatitis C treatment subsidies, and analyzing stroke prevention therapies. She has published extensively on HTA methodologies and their application in formulary management and drug pricing policies.

Professional roles include leadership in HTA since 2016, prior experience as a Principal Research Analyst at National Healthcare Group, and industry roles in medical affairs and market research. Her work bridges academic research with practical healthcare policy implementation, focusing on sustainable healthcare systems.

Publications highlight interdisciplinary approaches to assessing innovative treatments, balancing clinical efficacy with economic viability. Recent work explores emerging technologies through horizon scanning to inform future healthcare strategies. She actively contributes to Singapore's healthcare policy landscape through evidence-based decision-making frameworks.